Dr. Jonathan Alan Abelson, MD

Dr. Abelson practices at Coastal Radiation Oncology Medical Group Inc - HOPD in Ventura, California.

Dr. Abelson's NPI, 1730348053, was assigned on June 2, 2008. Dr. Abelson graduated from David Geffen School of Medicine at UCLA in 2007. Dr. Abelson holds California license A105322.

Dr. Abelson's primary practice is Coastal Radiation Oncology Medical Group Inc - HOPD, at 2900 Loma Vista Rd, Ventura, CA 93003.

Dr. Abelson's primary practice is Coastal Radiation Oncology Medical Group Inc - HOPD in Ventura, California. Dr. Abelson is also affiliated with Los Robles Regional Medical Center. The medical group on file is Coastal Radiation Oncology. Dmand AI also links Dr. Abelson to 1 more group practice or clinic and 1 medical group, each named with a free account. Dr. Abelson's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abelson practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Abelson's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Abelson is board certified in radiation oncology by the American Board of Radiology. Dr. Abelson is licensed in California.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, colorectal cancer radiation, head & neck cancer radiation and lung cancer radiation among the conditions Dr. Abelson treats.

CMS data shows 4,245 Medicare services from Dr. Abelson across 22 procedure codes in 2024, for 248 Medicare patients. Medicare paid $865,226 for them.

CMS counts 248 Medicare patients who saw Dr. Abelson in 2024. The largest group is 75 to 84, with 105 patients. 75% of them have cancer, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abelson's median patient age at 70, with 55% women.

In 2024, Dr. Abelson wrote 56 Medicare Part D claims for 26 patients. 96% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $167 in total drug cost. In 2021, CMS named 24 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Abelson for performance year 2024, reported individually. Dr. Abelson accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Abelson, published from 2010 to 2023. 2011 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Radiosurgery and Adenocarcinoma. Dr. Abelson's most frequent co-authors are Quynh-Thu Xuan Le, MD, Billy W. Loo, MD, PhD and James Don Murphy, MD.

Dmand AI links Dr. Abelson to 1 clinical trial. Conditions studied include Mesothelioma and Neoplasms, Mesothelial.

CMS Open Payments shows 23 general payments to Dr. Abelson from 10 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $186.

Dr. Abelson graduated from David Geffen School of Medicine at UCLA in 2007.

Dr. Abelson is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.